| 000 | 01765cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030901.0 | ||
| 008 | 131102s2013 ua f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.33.Ph.D.2013.Ha.F | ||
| 100 | 0 | _aHaitham Ahmed Ali Gabr | |
| 245 | 1 | 0 |
_aFluvastatin as an adjuvant therapy with pegylated interferon and ribavirin in the treatment of chronic hepatitis C virus / _cHaitham Ahmed Ali Gabr ; Supervised Zakaria A. Salama , Moataz Serry Seyam , Ahmed Fouad Soliman |
| 246 | 1 | 5 | _aالفلوفاستاتين كعقار مساعد لعقاري الانترفيرون طويل المفعول و الريبافيرين فى علاج الالتهاب الكبدى الوبائى الفيروسي (سى) المزمن |
| 260 |
_aCairo : _bHaitham Ahmed Ali Gabr , _c2013 |
||
| 300 |
_a288 P. ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine | ||
| 520 | _aIt could be argued that statins, besides a weak direct antiviral effect, may enhance HCV infectivity of hepatocytes through the decrease in circulating LDL levels and the up-regulation of LDL receptors. This effect of statins might counterbalance the antiviral activity described in the replicon models | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aFluvastatin | |
| 653 | 4 | _aStatins and HCV | |
| 653 | 4 | _aTreatment of HCV | |
| 700 | 0 |
_aAhmed Fouad Soliman , _eSupervisor |
|
| 700 | 0 |
_aMoataz Serry Seyam , _eSupervisor |
|
| 700 | 0 |
_aZakaria Abdellateef Salama , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c43962 _d43962 |
||